Adefovir-dipivoxil/lamivudineDevelopment of drug resistance and treatment failure in chronic hepatitis-B infection: 28 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2021年 / 1855卷 / 1期
关键词：
D O I：
10.1007/s40278-021-95694-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：18 / 18
相关论文
共 50 条
  • [41] Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B
    Santantonio, Teresa
    Fasano, Massimo
    Durantel, Sandra
    Barraud, Luc
    Heichen, Manuela
    Guastadisegni, Angela
    Pastore, Giuseppe
    Zoulim, Fabien
    ANTIVIRAL THERAPY, 2009, 14 (04) : 557 - 565
  • [42] Resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.
    Osiowy, C
    Heathcote, J
    Zoulim, F
    Willems, B
    Villeneuve, JP
    HEPATOLOGY, 2005, 42 (04) : 586A - 587A
  • [43] Determinants of virological response and resistance to adefovir treatment in chronic hepatitis B infection
    Ceylan, Bahadir
    Fincanci, Muzaffer
    Muderrisoglu, Cuneyt
    Soysal, Ferda
    Eren, Gulhan
    KLIMIK JOURNAL, 2008, 21 (02) : 45 - 49
  • [44] Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine
    Marugan, RB
    Gomez, LC
    Serrano, PL
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (05) : 1841 - 1843
  • [45] Adefovir dipivoxil/entecavir/lamivudineBreakthrough hepatitis, lymph node enlargement, dyspnoea and development of multi-drug resistance in chronic hepatitis B: case report
    Reactions Weekly, 2014, 1531 (1) : 17 - 17
  • [46] Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
    Wang, Guiliang
    Liu, Yan
    Qiu, Ping
    Zhou, Shu-Feng
    Xu, Linfang
    Wen, Ping
    Wen, Jianbo
    Xiao, Xianzhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2839 - 2846
  • [47] Potential addition to treatment of hepatitis B virus infection - Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks - Editorial comment
    Yang, H
    Westland, CE
    Delaney, WE
    INFECTIONS IN MEDICINE, 2002, 19 (11) : 507 - 508
  • [48] Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB)
    Chang, T. T.
    Shiffman, M. L.
    Tong, M.
    Liaw, Y. F.
    Komolmit, P.
    Sorbel, J.
    Arterburn, S.
    Mondou, E.
    Chuck, S.
    Marcellin, P.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S93 - S93
  • [49] Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
    Delaney, William E.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (05) : 827 - 832
  • [50] Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)
    Chang, TT
    Shiffman, M
    Tong, M
    Marcellin, P
    Liaw, YF
    Luengrojanakul, P
    Choy, GS
    James, C
    Ma, I
    Xiong, S
    Currie, G
    Brosgart, CL
    JOURNAL OF HEPATOLOGY, 2004, 40 : 126 - 126
12345